Tarrytown, New York, USA, November 17, 2026
Regeneron Pharmaceuticals, Inc. has announced that the European Commission (EC) has approved an alternative dosing schedule for Libtayo® (cemiplimab), offering greater flexibility for patients receiving treatment for multiple types of cancer. The approval introduces an extended dosing option of 700 mg administered intravenously every six weeks, following an initial 12-week treatment period with 350 mg every three weeks. Additionally, the updated authorization allows eligible patients receiving the 350 mg dose to benefit from shorter infusion times, potentially reducing subsequent administration from 30 minutes to just 15 minutes. The regulatory decision represents an important development in improving treatment convenience for patients with advanced cancers while providing healthcare professionals with additional flexibility in managing immunotherapy administration.
Extended Dosing Schedule Offers Greater Treatment Flexibility
Under the newly approved European dosing regimen, patients can receive Libtayo 350 mg every three weeks for the initial 12 weeks, with each infusion administered over 30 minutes. Following this initial treatment period, patients have the option to transition to a higher dose of 700 mg every six weeks, also administered through a 30-minute intravenous infusion. This alternative schedule reduces the frequency of maintenance treatment visits while maintaining an established therapeutic approach. The approval is expected to help reduce the practical burden associated with frequent hospital and clinic visits, particularly for individuals undergoing long-term cancer treatment. By introducing a six-week dosing interval, the updated regimen provides an additional treatment option for patients and healthcare providers across the approved indications. The change is particularly relevant in oncology care, where treatment schedules can place considerable demands on patients, caregivers and clinical teams.
Faster Infusion Times Across Approved Cancer Indications
In addition to extended dosing, the European Commission has approved an option to reduce subsequent infusion times for Libtayo 350 mg from 30 minutes to 15 minutes. This shorter administration time is available for patients whose first 30-minute infusion at the 350 mg dose level has been well tolerated. Depending on individual circumstances, subsequent infusions may therefore be administered over 15 to 30 minutes. The flexibility could help reduce time spent at treatment facilities and improve the overall convenience of receiving immunotherapy. According to Regeneron, the updated dosing options are intended to address practical challenges associated with advanced cancer treatment while supporting healthcare providers in delivering care more efficiently. The approval applies across all six approved Libtayo indications in the European Union, covering several important skin, lung and cervical cancer settings. These indications include advanced or metastatic cutaneous squamous cell carcinoma (CSCC), adjuvant treatment for CSCC patients at high risk of recurrence following surgery and radiation, and locally advanced or metastatic basal cell carcinoma (BCC) following progression on or intolerance to hedgehog pathway inhibitor treatment. The authorization also covers first-line treatment of eligible patients with non-small cell lung cancer (NSCLC), both as monotherapy in selected patients with high PD-L1 expression and in combination with platinum-based chemotherapy for eligible patients with PD-L1-positive disease. Additionally, Libtayo remains an approved treatment option for adults with recurrent or metastatic cervical cancer whose disease has progressed during or following platinum-based chemotherapy.
Clinical Evidence and PD-1 Immunotherapy Development
The European Commission’s decision is supported by clinical safety and efficacy data from Libtayo’s clinical development program, integrated with comprehensive pharmacokinetic (PK) and pharmacodynamic (PD) modelling and simulation data. These analyses support the alternative dosing schedule and its application across the medicine’s approved European indications. Libtayo, whose generic name is cemiplimab, is a fully human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) immune checkpoint receptor on T cells. By blocking the PD-1 pathway, the medicine helps prevent cancer cells from suppressing T-cell activation, supporting the immune system’s ability to recognize and attack cancer cells. The treatment was developed using Regeneron’s proprietary VelocImmune® technology and has received regulatory approvals in more than 30 countries for one or more cancer indications. Regeneron also confirmed that a supplemental Biologics License Application (sBLA) covering the alternative dosing regimen is currently under review in the United States, with a regulatory decision expected in March 2027. The European approval therefore marks an important regulatory milestone for the company’s oncology portfolio and expands the available administration options for eligible patients. With its extended dosing interval and shorter infusion option, the updated Libtayo regimen highlights the continued focus of oncology drug development on combining established therapeutic approaches with more convenient treatment administration.
Source: Regeneron press release



